Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Université de Lomé, Département de Santé Publique, Lomé, Togo | UNKNOWN |
| Bichat Hospital | OTHER |
| Espoir Vie-Togo - ONG | OTHER |
| Centre Africain de Recherche en Epidémiologie et en Santé Publique, Lomé, Togo |
Not provided
Not provided
Not provided
Not provided
The DepIST-H study, funded by the French AIDS and Hepatitis Research Agency (ANRS), is to estimate prevalence (the number of cases over a given period of time) and incidence (the number of new cases over a given period of time) of anal lesions (condylomas, dysplasia, cancers) by HIV status among MSM in Lomé, Togo
Title: Prevalence and longitudinal follow-up over 2 years of anal lesions, HPV infection and associated sexually transmitted infections among men who have sex with men (MSM) in Lomé, Togo (ANRS12400 DepIST-H)
Main objective: To estimate the prevalence and incidence of anal lesions (condyloma, dysplasia and anal cancers) according to HIV status among MSM in Lomé, Togo
Specific objectives :
To estimate the prevalence of HPV infection at baseline (M0) at anal and oropharyngeal sites To describe the persistence of HPV infection at Year 1 and 2 at the anal and oropharyngeal sites To describe the recurrence of anal lesions at Year 1 and 2 To estimate prevalence and incidence of associated STIs (Neisseria gonorrhoeae, Chlamydia trachomatis, Herpes simplex Virus type 2, Mycoplasma genitalium, Trichomonas vaginalis) HBV, HCV and syphilis
Methods :
This study is a prospective cohort with a 2-year follow-up of 200 MSM in Lomé (100 HIV- and 100 HIV+). Three data collection systems are integrated into the cohort: (i) clinical data, (ii) socio-behavioural questionnaires, and (iii) biological data.
Sample size: 200 participants (100 HIV+ and 100 HIV-)
Interventions :
Screening for anal dysplasia, HPV infection, HIV infection and several STIs (Neisseria gonorrhoeae, Chlamydia trachomatis, Mycoplasma genitalium, Trichomonas vaginalis, HSV-2 and HBV).
Offering comprehensive care including prevention strategies adapted to the various STIs mentioned above and their complications, particularly the progression to anal cancer for HPV infections in MSM.
Statistical analysis methods :
Use of mixed approaches. For quantitative indicators, descriptive analysis techniques, bivariate analysis (Student t test or Wilcoxon test for quantitative variables, Chi² or Fisher test for categorical variables) and multivariate analysis (logistic regression).
To estimate the incidence if the STIs, Kaplan-Meier curves, Cox models analyses will be conducted.
As the cohort is open and non-randomized, preliminary analyses will be conducted during the collection.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| STIs screening and care | Other |
|
| Measure | Description | Time Frame |
|---|---|---|
| Prevalence at inclusion of anal lesions | According to HIV status among MSM in Lomé, Togo | at Day 0 |
| Measure | Description | Time Frame |
|---|---|---|
| Prevalence of anal lesions at baseline | According to HIV status among MSM in Lomé, Togo | at Day 0 |
| Incidence of anal lesions | According to HIV status among MSM in Lomé, Togo |
| Measure | Description | Time Frame |
|---|---|---|
| Prevalence of others STIs : N. gonorrhoeae, C. trachomatis, M. genitalium, T. vaginalis, Herpès Simplex Virus type 2 (HSV-2), syphilis, hepatitis B and hepatitis C | According to HIV status | At Day 0, at 12 month and 24 month |
| Incidence of others STIs : Neisseria gonorrhoeae, Chlamydia trachomatis, Mycoplasma genitalium, Trichomonas vaginalis and Herpès Simplex Virus type 2 (HSV-2), syphilis, hepatitis B and hepatitis C |
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Male who have sex with men living with HIV or not
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Didier Koumavi Ekouevi | Contact | +228 99 68 67 35 | didier.ekouevi@gmail.com | |
| Arnold Sadio | Contact | sadioarnold@gmail.com |
| Name | Affiliation | Role |
|---|---|---|
| Charlotte Charpentier | Hôpital Bichat Claude Bernard, Paris, France | Principal Investigator |
| Didier Ekouevi | Lomé University, Togo | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| ONG, Espoir Vie Togo | Recruiting | Lomé | Togo |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 41013315 | Derived | Ferre VM, Sadio AJ, Gbeasor-Komlanvi FA, Bucau M, Salou M, Bercot B, Bebear C, Abramowitz L, Zaidi M, Amenyah-Ehlan AP, Mensah E, Braille A, Couvelard A, Dagnra AC, Ghosn J, Descamps D, Charpentier C, Ekouevi DK. High prevalence of bacterial STI, anal HPV, cytological abnormalities and anal lesions among MSM in Togo, 2021: a baseline analysis of the ANRS I MIE 12,400/DepIST-H cohort. BMC Infect Dis. 2025 Sep 26;25(1):1156. doi: 10.1186/s12879-025-11338-y. |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| UNKNOWN |
| Programme PAC-CI, Site ANRS-MIE de Côte d'Ivoire | OTHER |
| Laboratoire de Biologie Moléculaire et d'Immunologie, Lomé, Togo | UNKNOWN |
| Saint-Louis Hospital, Paris, France | OTHER |
| University Hospital, Bordeaux | OTHER |
Not provided
Not provided
Not provided
Urine, Blood Anal smear pharyngeal and oral specimens urethral specimens Swab of herpes vesicles
| at 12 month and 24 month |
| Describe the number of worsening events of anal cytological lesions | According to HIV status among MSM in Lomé, Togo | at 12 month and 24 month |
| Describe the proportion of recurrence of anal lesions | According to HIV status among MSM who received available treatment, in Lomé, Togo | at 12 month and 24 month |
| Prevalence of HPV infections | at Day 0 |
| Incidence of HPV infection | at 12 month and 24 month |
| Describe the proportion of persistent HPV infections | at 12 month and 24 month |
| Describe the proportion of clearance of HPV infections | in the same individual, on anal and oral specimens, based on HIV status. | at 12 month and 24 month |
According to HIV status |
| At Day 0, at 12 month and 24 month |
| Determination of different Chlamydia trachomatis strains | At Day 0 |
| Determination of antibiotic resistance profiles for Neisseria gonorrhoeae, Mycoplasma genitalium and Chlamydia trachomatis | According to HIV status | At Day 0 |
| Incidence of HIV | at 12 month and 24 month |
| ID | Term |
|---|---|
| D030361 | Papillomavirus Infections |
| D015658 | HIV Infections |
| ID | Term |
|---|---|
| D015229 | Sexually Transmitted Diseases, Viral |
| D012749 | Sexually Transmitted Diseases |
| D003141 | Communicable Diseases |
| D007239 | Infections |
| D004266 | DNA Virus Infections |
| D014777 | Virus Diseases |
| D014412 | Tumor Virus Infections |
| D000091662 | Genital Diseases |
| D000091642 | Urogenital Diseases |
| D020969 | Disease Attributes |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D000086982 | Blood-Borne Infections |
| D016180 | Lentivirus Infections |
| D012192 | Retroviridae Infections |
| D012327 | RNA Virus Infections |
| D007153 | Immunologic Deficiency Syndromes |
| D007154 | Immune System Diseases |
Not provided
Not provided